Literature DB >> 2005328

Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics.

J Bousquet1, A Hejjaoui, W M Becker, P Cour, I Chanal, B Lebel, H Dhivert, F B Michel.   

Abstract

The heterogeneity of pollen-allergic individuals is well-known but poorly characterized. Twenty-six patients were studied to characterize their immunologic and clinical patterns. Thirteen patients were allergic only to grass pollens, and 13 other patients were allergic to grass-pollen and other pollen species, including Cupressaceae, plane tree, olive, and Parietaria. The IgE response was assessed by the titration of serum total IgE and orchard grass-specific IgE, as well as by IgE immunoblots to orchard-grass pollens. Clinical reactivity was assessed by nasal challenge with orchard-grass pollens before the pollen season and nasal and bronchial symptom-medication scores between April 1 and June 15. Pollen counts were obtained during this period of survey. Polysensitized patients had significantly increased levels of serum total and specific IgE and a greater heterogeneity of IgE immunoblots, suggesting an enhanced qualitative and quantitative IgE immune response. Polysensitized patients had nasal and bronchial symptoms occurring earlier than grass pollen-allergic individuals, confirming the priming effect caused by other plans flowering with an earlier season for both nasal and bronchial mucosa. Alternatively, the early symptoms may be attributable to the tree pollens or might reflect the higher grass-pollen IgE level in the polysensitized group. Bronchial symptoms appeared a few weeks after nasal symptoms. Nasal challenges were similar in both groups, and the severity of nasal symptoms during the season was not significantly different in both groups, suggesting that the intensity of symptoms is not related to the sensitization nor to the IgE immune response of the subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005328     DOI: 10.1016/0091-6749(91)90397-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.

Authors:  C Barth; F Anero; O Pfaar; L Klimek; K Hörmann; B A Stuck
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-09       Impact factor: 2.503

2.  Differences in IL-4 release by PBMC are related with heterogeneity of atopy.

Authors:  J Pène; A Rivier; B Lagier; W M Becker; F B Michel; J Bousquet
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

3.  In children allergic to ragweed pollen, nasal inflammation is not influenced by monosensitization or polysensitization.

Authors:  Matteo Gelardi; Mariangela Bosoni; Marco Morelli; Silvia Beretta; Cristoforo Incorvaia; Serena Buttafava; Massimo Landi; Simonetta Masieri; Franco Frati; Nicola Quaranta; Gian Vincenzo Zuccotti
Journal:  J Inflamm Res       Date:  2016-04-05

4.  Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by Escherichia coli Nissle 1917 Prevents Allergic Poly-Sensitization in Mice.

Authors:  Priya J Sarate; Dagmar Srutkova; Nora Geissler; Martin Schwarzer; Irma Schabussova; Aleksandra Inic-Kanada; Hana Kozakova; Ursula Wiedermann
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

5.  Short term physician visits and medication prescriptions for allergic disease associated with seasonal tree, grass, and weed pollen exposure across the United States.

Authors:  Shubhayu Saha; Ambarish Vaidyanathan; Fiona Lo; Claudia Brown; Jeremy J Hess
Journal:  Environ Health       Date:  2021-07-21       Impact factor: 5.984

Review 6.  Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015.

Authors:  J Bousquet; J M Anto; M Akdis; C Auffray; T Keil; I Momas; D S Postma; R Valenta; M Wickman; A Cambon-Thomsen; T Haahtela; B N Lambrecht; K C Lodrup Carlsen; G H Koppelman; J Sunyer; T Zuberbier; I Annesi-Maesano; A Arno; C Bindslev-Jensen; G De Carlo; F Forastiere; J Heinrich; M L Kowalski; D Maier; E Melén; S Palkonen; H A Smit; M Standl; J Wright; A Asarnoj; M Benet; N Ballardini; J Garcia-Aymerich; U Gehring; S Guerra; C Hohman; I Kull; C Lupinek; M Pinart; I Skrindo; M Westman; D Smagghe; C Akdis; R Albang; V Anastasova; N Anderson; C Bachert; S Ballereau; F Ballester; X Basagana; A Bedbrook; A Bergstrom; A von Berg; B Brunekreef; E Burte; K H Carlsen; L Chatzi; J M Coquet; M Curin; P Demoly; E Eller; M P Fantini; B Gerhard; H Hammad; L von Hertzen; V Hovland; B Jacquemin; J Just; T Keller; M Kerkhof; R Kiss; M Kogevinas; S Koletzko; S Lau; I Lehmann; N Lemonnier; R McEachan; M Mäkelä; J Mestres; E Minina; P Mowinckel; R Nadif; M Nawijn; S Oddie; J Pellet; I Pin; D Porta; F Rancière; A Rial-Sebbag; Y Saeys; M J Schuijs; V Siroux; C G Tischer; M Torrent; R Varraso; J De Vocht; K Wenger; S Wieser; C Xu
Journal:  Allergy       Date:  2016-08-23       Impact factor: 13.146

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.